← Oncology Approval Tracker

FDA DECISION ·

Fylnetra

pegfilgrastim-pbbk · Kashiv BioSciences

Biosimilar approvalBiosimilarChemotherapy-associated febrile neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Pegfilgrastim biosimilar for reduction of infection manifested as febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant risk.

LAMPGEN ANALYSIS

Why it matters

This adds a long-acting growth factor product to an established prevention setting.

What research teams should watch

Track product suffix and confirm timing relative to myelosuppressive treatment.

PRIMARY RECORDS

Sources